Phoenix Asia Holdings Limited announced it will acquire 100% of ACEA Pharma, a clinical-stage pharmaceutical company, by issuing 100 million new shares valued at $1 billion. The acquisition is expected to close in Q2 2026, pending regulatory approvals including antitrust and Nasdaq clearance. Additionally, Phoenix Asia issued a $20 million convertible promissory note to its controlling shareholder as payment for advisory services. This marks Phoenix Asia's strategic shift from construction to becoming a pharmaceutical holding company.
Pepeto's presale has raised over $10.27 million and is preparing for a Binance listing amid a forming crypto bull run, promising strong potential gains similar to past Binance token launches. Meanwhile, Standard Chartered predicts XRP could reach $8 ...
Ready Capital Corporation announced quarterly cash dividends for Q2 2026. Common stockholders and Operating Partnership unit holders will receive $0.01 per share payable on July 31, 2026. Additionally, dividends of $0.390625 per share for Series C Pr...
Terra Innovatum Global filed its 2025 Annual Report on Form 10-K, marking its first full year as a public company. The company ended fiscal 2025 with $102.9 million in cash and no debt, supported by proceeds from its business combination with GSR III...
ARC Resources Ltd. announced a quarterly eligible dividend of $0.21 per share payable on July 15, 2026, to shareholders recorded by June 30, 2026. The company, a major Montney producer in Canada, has paid a total of $0.80 per share over the past 12 m...
The Lovesac Company has named Andrew Farag as its new Executive Vice President, Chief Financial Officer, and Treasurer, effective immediately. Farag brings over 20 years of experience in finance and operations, having held CFO and COO roles in variou...
